Antiserum against leukemia cell ferritin as a diagnostic tool for malignant neoplasms.
The specific antiserum against a type of ferritin that is especially common to leukemia cells and the placenta was used to test, by countercurrent immunoelectrophoresis, sera from humans with various diseases. The best results were obtained with leukemia; patients with chronic myelogenous leukemia in blastic phase, acute myelogenous leukemia, lymphogenous leukemia, and unclassifiable juvenile leukemia frequently showed a positive reaction, but patients with chronic myelogenous leukemia in static phase did not. The average incidence of positive reaction among all leukemia patients was 54.0%. Patients with other malignant tumors (i.e., multiple myeloma, malignant lymphoma and carcinomas of the stomach, rectum, and liver) also often showed a positive reaction. The average incidence of positive reaction among all the patients with malignant diseases of the hematopoietic system, except for leukemia, was 34.3%, and that among patients with nonhematologic malignant neoplasms was 36.8%. However, the incidence of a positive reaction in patients with benign diseases and healthy individuals was less than 3%.
D003378:Counterimmunoelectrophoresis; D005293:Ferritins / Q000276:immunology*; D006801:Humans; D007938:Leukemia / Q000097:blood*; D007945:Leukemia, Lymphoid / Q000175:diagnosis; D007951:Leukemia, Myeloid / Q000175:diagnosis; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis; D008113:Liver Neoplasms / Q000175:diagnosis; D008223:Lymphoma / Q000175:diagnosis; D009101:Multiple Myeloma / Q000175:diagnosis; D009369:Neoplasms / Q000175:diagnosis*; D010920:Placenta / Q000276:immunology; D012004:Rectal Neoplasms / Q000175:diagnosis; D013274:Stomach Neoplasms / Q000175:diagnosis
D005293:Ferritins